Biosimilar Product Differences Will Affect US Uptake, Amgen Predicts
Executive Summary
Differences in product characteristics should be considered in formulary decisions, Amgen says in annual trends report that puts its biosimilars in a strong competitive light while also bolstering the position of its reference biologics.